Cardioprotection: Emerging pharmacotherapy

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 5, 2001, Pages 739-752

  Gumina, R J ^a   Jahangir, A ^a   Gross, G J ^a   Terzic, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adenosine; Antineutrophils; Cardioprotection; Clinical trials; Magnesium; Myocardial infarction; Opioids; Potassium channel openers; Sodium hydrogen exchanger inhibitors

Indexed keywords

ADENOSINE DERIVATIVE; ADENOSINE TRIPHOSPHATASE (POTASSIUM); ADENOSINE TRIPHOSPHATE; CALCIUM ION; CARDIAC AGENT; CARIPORIDE; GLUCOSE; GLYCOGEN; INSULIN; LACTIC ACID; MAGNESIUM DERIVATIVE; MAGNESIUM ION; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD18; NEUTROPHIL CYTOPLASMIC ANTIBODY; NICORANDIL; OPIATE; OPIATE ANTAGONIST; OPIATE RECEPTOR; PLACEBO; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; POTASSIUM DERIVATIVE; PROTECTIVE AGENT; PROTEIN KINASE C; PROTON; SODIUM ION; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE DISEASE; CAUSE OF DEATH; CELL DAMAGE; CELL DEATH; CHEMOPROPHYLAXIS; CLINICAL STUDY; CONTROLLED STUDY; CORONARY REPERFUSION; DISEASE PREDISPOSITION; DRUG MECHANISM; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; PREDICTION; REGULATORY MECHANISM; REVIEW; SURVIVAL RATE; TREATMENT PLANNING;

HEART; HUMANS; ISCHEMIC PRECONDITIONING; MAGNESIUM; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; POTASSIUM CHANNELS; PROTECTIVE AGENTS; RECEPTORS, PURINERGIC P1; SODIUM-HYDROGEN ANTIPORTER;

EID: 0034876552     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.5.739     Document Type: Review

References (105)

1. The global burden of disease, 1990-2020
2. The pathogenesis of coronary artery disease and the acute coronary syndromes
3. The pathogenesis of coronary artery disease and the acute coronary syndromes
4. Studies of experimental coronary artery reperfusion: Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage
5. Thrombolysis and myocardial salvage: Results of clinical trials and the animal paradigm - Paradoxic or predictable?
6. Link Between the Angiographic Substudy and Mortality Outcomes in a Large Randomized Trial of Myocardial Reperfusion: Importance of Early and Complete Infarct Artery Reperfusion
7. Time to therapy and salvage in myocardial infarction
8. New frontiers of cardioprotection
9. Protective effects of adenosine in myocardial ischemia
10. Adenosine for myocardial protection in acute myocardial infarction
11. ATP-sensitive potassium channels and myocardial preconditioning
12. + channels and myocardial preconditioning
13. Signal transduction in ischemic preconditioning: The role of kinases and mitochondrial K(ATP) channels
14. Ischaemic preconditioning: Present position and future directions
15. The leukocyte cell adhesion cascade and its role in myocardial ischemia-reperfusion injury
16. Protons in ischemia: Where do they come from; where do they go to?
17. The sodium/hydrogen exchange system in cardiac cells: Its biochemical and pharmacological properties and its role in regulating internal concentrations of sodium and internal pH
18. + concentration. A molecular basis for the antagonistic effect of ouabain and amiloride on the heart
19. 2+ exchange
20. Correlation between cytosolic free calcium, contracture, ATP and irreversible ischemic injury in perfused rat heart
21. Reperfusion injury: Manifestations, mechanisms and clinical relevance
22. Role of leukocytes in response to acute myocardial ischemia and reflow in dogs
23. Inflammation in the course of early myocardial ischemia
24. Postreperfusion inflammation: A model for reaction to injury in cardiovascular disease
25. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium
26. What is ischemic preconditioning?
27. Does ischemic preconditioning occur in patients?
28. Previous angina alters in-hospital outcome in TIMI 4: A clinical correlate to preconditioning?
29. Preinfarction angina as a major predictor of left ventricular function and long-term prognosis after a first Q wave myocardial infarction
30. Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5′-nucleotidase activity and attenuation of adenosine release
31. Myocardial protection with preconditioning
32. Direct Preconditioning of Cultured Chick Ventricular Myocytes. Novel Functions of Cardiac Adenosine A2a and A3 Receptors
33. Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5′-nucleotidase
34. Phosphorylation state of hsp27 and p38 MAPK during preconditioning and protein phosphatase inhibitor protection of rabbit cardiomyocytes
35. + channels by protein kinase C
36. Ischemic preconditioning in the intact rat heart is mediated by delta1- but not mu- or kappa-opioid receptors
37. TAN-67, a delta 1-opioid receptor agonist, reduces infarct size via activation of Gi/o proteins and KATP channels
38. The ATP-regulated potassium channel in ischemia-reperfusion injury
39. Medical and cellular implications of stunning, hibernation and preconditioning
40. Pharmacology of ATP-sensitive potassium channel openers in models of myocardial ischemia and reperfusion
41. + channel subunits confer resistance to chemical hypoxia-reoxygenation injury
42. + channels in cardiac muscle
43. + channel-opening drugs
44. + channels: Possible mechanism of cardioprotection
45. + channels modulate cardiac mitochondrial function
46. 2+ overload in rat cardiac mitochondria
47. Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart
48. Ischemic preconditioning in rats: Role of mitochondrial K(ATP) channel in preservation of mitochondrial function
49. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction
50. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction
51. Cardioprotective effect of intravenous nicorandil in patients with successful reperfusion for acute myocardial infarction
52. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical studies in angina and revascularization
53. Receptors for purines and pyrimidines
54. Adenosine and cardioprotection during ischaemia and reperfusion - An overview
55. Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology and pharmacology
56. Ionic basis of the electro physiological actions of adenosine on cardiomyocytes
57. 2+ current inhibition
58. Adenosine attenuates calcium paradox injury: Role of adenosine A1 receptor
59. 2+ loading: Insight into cardioprotection during cardioplegia
60. Intravenous pretreatment with A sub 1-selective adenosine analogs protects the heart against infarction
61. Pretreatment with the adenosine A sub 1 receptor agonist 2-chloro-N sup 6-cyclopentyladenosine (CCPA), causes a sustained limitation of infarct size in conscious rabbits
62. + channels
63. Role of nitric oxide in adenosine receptor-mediated relaxation of porcine coronary artery
64. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence
65. 1 receptor-mediated antiadrenergic effects in the rat myocardium
66. A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury
67. Adenosine receptor specificity in preconditioning of isolated rabbit cardiomyocytes: Evidence of A3 receptor involvement
68. Selective activation of A3 adenosine receptors with N6-(3-Iodobenzyl)adenosine-5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits
69. Protein kinase C-dependent activation of KATP channel enhances adenosine-induced cardio-protection
70. + channels to A1 receptors by G proteins in rat ventricular myocytes
71. Contribution of ATP-sensitive potassium channels to the electro-physiological effects of adenosine in guinea-pig atrial cells
72. Effects of A1 adenosine receptor blockade by bamiphylline on ischaemic preconditioning during coronary angioplasty
73. Intravenous adenosine and lidocaine in patients with acute myocardial infarction
74. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial
75. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction
76. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of 'no reflow' phenomenon
77. Effects of naloxone on myocardial ischemic preconditioning in humans
78. The sodium-hydrogen exchange system in the heart: Its role in ischemic and reperfusion injury and therapeutic implications
79. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN Trial
80. +) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA
81. Magnesium and cardiovascular disease
82. Possible pharmacological actions of magnesium in acute myocardial infarction
83. The rationale of magnesium supplementation in acute myocardial infarction: A review of the literature
84. Magnesium in acute MI: Timing is critical
85. Magnesium: Nature's physiologic calcium blocker
86. Modulation of severity of reperfusion stunning in the isolated rat heart by agents altering calcium flux at onset of reperfusion
87. Effects of intravenous magnesium in suspected acute myocardial infarction: Overview of randomised trials
88. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts: Treatments for myocardial infarction
89. Randomized trials of magnesium in acute myocardial infarction: Big numbers do not tell the whole story
90. Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2)
91. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction
92. Rationale and design of the magnesium in coronaries (MAGIC) study: A clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarction
93. Glucose and the metabolism of ischaemic myocardium
94. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction
95. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: An overview of randomized placebo-controlled trials
96. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year
97. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus
98. Metabolic modulation of acute myocardial infarction: The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group
99. The Effect of a CD11/CD18 Inhibitor (Hu23F2G) on Infarct Size Following Direct Angioplasty: The HALT MI Study
100. LIMIT AMI (Limitation of Myocardial Injury following Thrombolysis in Acute Myocardial Infarction) An angiographic safety and efficacy trial of a novel anti-CD18 therapy in acute myocardial infarction in conjunction with thrombolysis
101. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: Distant dream or near reality?
102. Anti-ischemic effect of a novel cardioprotective agent, JTV519, is mediated through specific activation of delta-isoform of protein kinase C in rat ventricular myocardium
103. 2+ exchanger
104. + exchanger for protection of the myocardium from lethal reperfusion injury
105. 2+ exchange at the time of myocardial reperfusion limits hypercontracture and cell death